Chiral gives researchers instant, AI-powered access to the information and tools they need to make faster, smarter decisions. Chiral is an AI-driven drug discovery platform that streamlines research workflows, helping scientists save millions and focus on real innovation. Up to 40% of R&D budgets in drug discovery are wasted because researchers don’t have instant access to the data, tools, and insights they need to move forward.

Crafton Biotechnology Co., Ltd., established in March 2022 in Nagoya, Japan, is a biotechnology company focused on developing novel treatments for cancer, autoimmune, and infectious diseases through its foundational PureCap® technology. PureCap® is a proprietary capping technology to enhance the safety, stability and efficacy of mRNA, that has the potential to improve patient outcome compared to existing technologies. Committed to revolutionizing treatment options, Crafton aims to leverage fully chemically synthesized mRNA to significantly improve patient outcomes on a global scale.

Dioseve is a Tokyo-based biotech company developing innovative fertility treatments by applying iPS cell-derived ovarian technology. Its flagship product, DIOS-101, aims to dramatically improve in vitro maturation and expand fertility options for patients worldwide. Dioseve collaborates with leading clinics and research institutions to transform the future of reproductive medicine.

iBody Inc. is a biotechnology company with a proprietary antibody discovery platform that integrates single-cell analysis technology with a cell-free antibody expression system. This unique approach enables comprehensive and rapid identification of valuable antibodies from the immune systems of animals—antibodies that are often overlooked by conventional methods. The platform is particularly effective in the screening of high-affinity, high-specificity rabbit monoclonal antibodies, achieving a high success rate. iBody has a proven track record of contract and collaborative research with pharmaceutical and diagnostic companies, and academic institutions in Japan, and is now actively expanding its global presence. Through its antibody development services, iBody aims to drive innovation in the development of both therapeutic and diagnostic antibodies.

ModAstera is a Tokyo-based startup offering a powerful platform that dramatically streamlines the development and deployment of medical AI. With MAEA – our proprietary Medical AI Engineering Agent, we automate everything from data processing to model building, compliance, deployment – cutting development costs by up to 90% and enabling rapid creation of high-quality AI with no-code to full-code flexibility.

We develop Electrical Impedance Tomography (EIT) -based medical devices for the early detection and monitoring of lymphedema in hospitals and homes, thereby improving the quality of life for patients, mainly after breast cancer and gynecological cancer surgery. We are currently conducting clinical studies in lymphedema patients with the aim of establishing proof of concept.

Cosomil is a deep-tech startup for cancer screening with its proprietary ‘Single-molecule Enzyme Activity-based Liquid Biopsy’ technology that was developed by UTokyo & RIKEN. They are committed to delivering innovative solutions for early cancer detection for curative treatments such as the most lethal one, Pancreatic Cancer.

Plusman uses actuarial expertise to create advanced mathematical models and AI for medicine. Our solutions include diagnostic imaging AI, treatment planning support, medical generative AI, LLM, and Digital CDx, which predicts genetic mutations and suggests treatments based on medical data.

Rege Nephro Co., Ltd., a Kyoto University spin-off biotech startup, utilizes iPSC technology. Our lead products include RN-014, a small-molecule for autosomal dominant polycystic kidney disease (ADPKD), and RN-032, an allogeneic cell therapy for chronic kidney disease using iPSC-derived nephron progenitor cells.

SyntheticGestalt is a molecule-focused AI development company: our core technology is a foundation AI model trained on 1 billion compounds, which can be used to develop various high-performance AI models for small molecules with ease. We have already raised $14 million from Japanese and UK investors and have collaborations with major companies.

Abrax Japan, Inc. is a biotech company that harnesses the potential of an immune modulating protein called thymic stromal lymphopoietin (TSLP) for the treatment of multiple disorders including eczema, dry eye disease, obesity, obesity-related metabolic complications.

Citadel AI is a global leader in trustworthy AI technology and develops tools to evaluate, explain, and debug AI systems. Our products have been adopted by BSI (British Standards Institution). In addition, Citadel AI is trusted by public organizations such as the AI Safety Institute in the US.

The company uses "CUBIC," a three-dimensional analysis technology developed over years of research, to comprehensively analyze the distribution of drugs in organs and their cellular reactions across all organs and the entire body. They provide contract research services to pharmaceutical companies and also supply reagent kits for R&D scientists.

A start-up company from Kitasato University. Developing innovative hemodialysis device dedicated for home use, requiring only consumables (no water supply nor drainage required) to improve Quality of Life of patients with end-stage renal disease and their family. Product launch in Japan is planned in 2029.

Rebirthel provides a novel treatment method "Allogeneic off-the-shelf universal T cell therapy" for advanced and recurrent cancers that are not curative to current conventional therapies. Fundamental technologies that make this therapy realizable are patented globally. With the recently developed technology to avoid immune rejection, we provide the super universal therapy with benefits to patients.

Smart Tissues is developing the first antimicrobial and versatile bioink for bioprinting human tissues and organs. Smart Tissues' unique strength is the antimicrobial properties of their bioink and being the first bioink manufacturer in Japan.

Spine Chronicle Japan Co., Ltd.'s vision is "to create the best spinal implants for elderly patients." We wish to improve the surgical results for elderly patients with weak bones. We are developing safe and reliable surgical treatment for patients with spinal fractures and lumber spinal stenosis.